NICE scopes Sanofi/Regeneron's Zaltrap for colorectal cancer
This article was originally published in Scrip
Executive Summary
Sanofi/Regenron's Zaltrap (aflibercept) will shortly be up for review by NICE, the health technology appraisal institute for England and Wales, as a treatment for metastatic colorectal cancer that has progressed after oxaliplatin-based chemotherapy. The institute has put out for consultation its draft scope.